Myotonic Dystrophy Type 1 or Steinert's disease

Advances in Experimental Medicine and Biology

Volumn 724, Issue , 2012, Pages 239-257

  Romeo, Vincenzo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MEXILETINE; MODAFINIL; TESTOSTERONE; PROTEIN SERINE THREONINE KINASE; RNA BINDING PROTEIN;

ARTICLE; BLOOD EXAMINATION; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL FEATURE; DNA DETERMINATION; DRUG MEGADOSE; DRUG RESPONSE; ELECTROMYOGRAPHY; EYELID RECONSTRUCTION; GASTROINTESTINAL SYMPTOM; GENOTYPE PHENOTYPE CORRELATION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LUNG DISEASE; MENTAL DISEASE; MUSCLE DISEASE; MYOTONIA; MYOTONIC DYSTROPHY; PACEMAKER; PALLIATIVE THERAPY; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; PTOSIS; RNA SPLICING; SLIT LAMP; SOMNOLENCE; ELECTROCARDIOGRAPHY; GENETICS; HISTORY; MUSCLE; PATHOLOGY; PATHOPHYSIOLOGY; PHOTOGRAPHY; REVIEW; TRINUCLEOTIDE REPEAT;

ELECTROCARDIOGRAPHY; ELECTROMYOGRAPHY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MUSCLES; MYOTONIC DYSTROPHY; PHOTOGRAPHY; PROTEIN-SERINE-THREONINE KINASES; RNA-BINDING PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84859521683     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0653-2_18     Document Type: Article

References (28)

1. Harper PS. Myotonic dystrophy. Ed. W. B. Saunders, third edition.
2. Brook JD, McCurrach ME, Harley HG et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992; 68:799-808.
3. Liquori CL, Ricker K, Moseley ML et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 ofZNF9. Science 2001; 293:864-867.
4. Lavedan C, Hofmann-Radvanyi H, Shelbourne P et al. Myotonic dystrophy: size- and sex-dependent dynamics of CTG meiotic instability and somatic mosaicism. Am J Hum Genet 1993; 52:875-883.
5. Thornton CA, Griggs RC, Moxley RT 3rd. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994; 35:269-272.
6. Udd B, Krahe R, Wallgren-Pettersson C et al. Proximal myotonic dystrophy-a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromusc Disord 1997; 7:217-228.
7. Moxley RT 3rd, Meola G, Udd B et al. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October, 2000, Loosdrecht, The Netherlands. Neuromuscul Disord 2002; 12:306-317.
8. New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium. Neurology 2000; 54:1218-1221.
9. de Die-Smulders CE, Howeler CJ, Thijs C et al. Age and causes of death in adult-onset myotonic dystrophy. Brain 1998; 121:1557-1563.
10. Reardon W, Newcombe R, Fenton I et al. The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Arch Dis Child 1993; 68:177-181.
11. Mathieu J, Boivin H, Meunier D et al. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001; 56:336-340.
12. Mathieu J, Allard P, Gobeil G et al. Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurology 49:1646-1650.
13. Melacini P, Buja G, Fasoli G et al. The natural history of cardiac involvement in myotoic dystrophy: an eight-yearfollow-upin 17patients. ClinCardiol 1988; 11:231-238.
14. Romeo V, Pegoraro E, Ferrati C et al. Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2. J Neurol 2010; 257:1246-1255.
15. Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 2007; 36:294-306.
16. Mastrogiacomo I, Bonanni G, Menegazzo E et al. Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy. Ital J Neurol Sci 1996; 17:59-65.
17. Barreca T, Muratorio A, Sannia A et al. Evaluation of twenty-four-hour secretory patterns of growth hormon and insulin in patients with myotonic dystrophy. J Clin Endocrinol Metab 51:1089-1092.
18. Moxley RT, Corbett AJ, Minaker KL et al. Whole body insulin resistance of myotonic dystrophy. Ann Neurology 1984; 15:157-162.
19. Dubowitz V. Muscle biopsy, 2nd edition. Philadelphia: WB Saunders, 1985.
20. Mussini I, Di Mauro S, Angelini C. Early ultrastructural and biochemical changes in muscle in dystrophia myotonica. J Neurol Sci 10:585-604.
21. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Gen Develop 2003; 17:419-437.
22. Day JW, Ranum LP. RNA pathogenesis of the myotonic dystrophies. Neuromusc Disord 2005; 15:5-16.
23. Logigian EL, Martens WB, Moxley RT 4th et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010; 74:1441-1448.
24. Griggs RC, Pandya S, Florence JM et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 1989; 39:219-222.
25. Moxley RT3rd. Potential for growth factor treatment of muscle disease. Curr Opin Neurol 1994; 7:427-434.
26. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy-a clinical research center study. J Clin Endocrinol Metab 1995; 80:3715-3723.
27. Maas O, PatersonAS. Mental changes in families affected by Dystrophia Myotonica. Lancet 1937; 1:21-23.
28. Annane D, Moore DH, Barnes PR et al. Psychostimulants for hypersomnia (excessive daytime sleepiness) inmyotonic dystrophy. Cochrane Database Syst Rev. 2002; 4:CD003218.